Ageing, oestrogen, platelets and thrombotic risk

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 8, 2007, Pages 814-821

  Miller, Virginia M ^a,b   Jayachandran, Muthuvel ^b   Owen, Whyte G ^a  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

17 oestradiol; Energy metabolism; Kronos Early Estrogen Prevention Study (KEEPS); Mitochondria; Women's Health Initiative

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; MITOCHONDRIAL DNA; PADGEM PROTEIN; RALOXIFENE; SEROTONIN; TAMOXIFEN;

AGING; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR RISK; ENERGY METABOLISM; ENZYME ACTIVATION; ESTROGEN THERAPY; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; MENSTRUAL CYCLE; MOUSE STRAIN; NONHUMAN; OXIDATIVE STRESS; REVIEW; RNA STABILITY; SWINE; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; THROMBOSIS;

AGE FACTORS; AGING; ANIMALS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; OXIDATIVE STRESS; PLATELET ACTIVATION; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RISK FACTORS; THROMBOSIS;

EID: 34347348973     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04685.x     Document Type: Review

References (94)

1. Wilkerson WR, Sane DC. Aging and thrombosis. Semin. Thromb. Hemost. 2002 28 : 555 68.
2. American Heart Association. Heart Disease and Stroke Statistics: 2003 Update. American Heart Association, Dallas, TX. 2002.
3. Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987 75 : 1102 9.
4. Stampfer MJ, Colditz GA, Willett WC. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the Nurses' Health Study. N. Engl. J. Med. 1991 325 : 756 62.
5. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998 280 : 605 13.
6. Barrett-Connor E, Grady D, Sashegyi A et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002 287 : 847 57.
7. Wassertheil-Smoller S, Hendrix SL, Limacher M et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: A randomized trial. JAMA 2003 289 : 2673 84.
8. Grady D, Herrington D, Bittner V et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002 288 : 49 57.
9. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 288 : 321 33.
10. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation. J. Women's Health 2006 15 : 35 44.
11. Joakimsen O, Bonaa KH, Stensland-Bugge E, Jacobsen BK. Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis. The Tromso Study. J. Clin. Epidemiol. 2000 53 : 525 30.
12. Hsia J, Langer RD, Manson JE et al. Conjugated equine estrogens and coronary heart disease. Arch. Intern. Med. 2006 166 : 357 65.
13. Walsh BW, Kuller LH, Wild RA et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998 279 : 1445 51.
14. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomized controlled trial. Arterioscler. Thromb. Vasc. Biol. 1997 17 : 3071 8.
15. Takkanen MJ. The menopause and hormone replacement therapy: Lipids, lipoproteins, coagulation and fibrinolytic factors. Maturitas 1996 23 : 209 16.
16. Straczek C, Oger E, de Jonage-Canonico BY et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration. Circulation 2005 112 : 3495 500.
17. Matz RL, Andriantsitohaina R. Age-related endothelial dysfunction. Potential implications for pharmacotherapy. Drug Aging 2003 20 : 527 50.
18. Brandes RP, Fleming I, Busse R. Endothelial aging. Cardiovasc. Res. 2005 66 : 286 94.
19. Radley JM, Haller CJ. The demarcation membrane system of the megakaryocyte: A misnomer? Blood 1982 60 : 213 19.
20. Leven RM. Megakaryocyte motility and platelet formation. Scanning Microsc. 1987 1 : 1701 9.
21. Ault KA, Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp. Hematol. 1995 23 : 996 1001.
22. Dale GL, Friese P, Hynes LA, Burstein SA. Demonstration that thiazole-orange-positive platelets in the dog are less than 24 hours old. Blood 1995 85 : 1822 5.
23. Denis MM, Tolley ND, Bunting M et al. Escaping the nuclear confines: Signal-dependent pre-mRNA splicing in anucleate platelets. Cell 2005 122 : 379 91.
24. McRedmond JP, Park SD, Reilly DF et al. Integration of proteomics and genomics in platelets: A profile of platelet proteins and platelet-specific genes. Mol. Cell. Proteomics 2004 3 : 133 44.
25. Nagata Y, Yoshikawa J, Hashimoto A, Yamamoto M, Payne AH, Todokoro K. Proplatelet formation of megakaryocytes is triggered by autocrine-synthesized estradiol. Genes Dev. 2003 17 : 2864 9.
26. Brass LF, Stalker TJ, Zhu L, Woulfe DS. Signal transduction during platelet plug formation. In : Michaelson AD (ed.). Platelets. Academic Press, San Diego. 2006 319 46.
27. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler. Thromb. Vasc. Biol. 2002 22 : 1381 9.
28. Karnicki K, Owen WG, Miller RS, McBane II RD. Factors contributing to individual propensity for arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 2002 22 : 1495 9.
29. Goldschmidt-Clermont PJ. Loss of bone marrow-derived vascular progenitor cells leads to inflammation and atherosclerosis. Am. Heart J. 2003 146 (Suppl. 4 S5 12.
30. Michimata T, Imamura M, Mizuma H, Murakami M, Iriuchijima T. Sex and age differences in soluble guanylate cyclase activity in human platelets. Life Sci. 1996 58 : 415 19.
31. Kumar AM, Weiss S, Fernandez JB, Cruess D, Eisdorfer C. Peripheral serotonin levels in women: Role of aging and ethnicity. Gerontology 1998 44 : 211 16.
32. Harro M, Eensoo D, Kiive E et al. Platelet monoamine oxidase in healthy 9- and 15-years old children: The effect of gender, smoking and puberty. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001 25 : 1497 511.
33. Podolsak B, Peter G, Oller J. Correlations between age-dependent protein and lipid concentrations in plasma and platelet functions in children. Eur. J. Pediatr. 1979 132 : 21 35.
34. McBride PA, Anderson GM, Hertzig ME et al. Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation. J. Am. Acad. Child. Adolesc. Psychiatry 1998 37 : 767 76.
35. Lommatzsch M, Zingler D, Schuhbaeck K et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Nueurobiol. Aging 2005 26 : 115 23.
36. Giannessi D, Andreassi MG, Del Ry S, Clerico A, Colombo MG, Dini N. Possibility of age regulation of the natriuretic peptide C-receptor in human platelets. J. Endocrinol. Invest. 2001 24 : 8 16.
37. Kurrelmeyer K, Becker L, Becker D, Yanek L, Goldschmidt-Clermont PJ, Bray PF. Platelet hyperreactivity in women from families with premature atherosclerosis. J. Am. Med. Womens Assoc. 2003 58 : 272 7.
38. Bord S, Frith E, Ireland DC, Scott MA, Craig JIO, Compston JE. Estrogen stimulates differentiation of megakaryocytes and modulates their expression of estrogen receptors α and β. J. Cell Biochem. 2004 92 : 249 57.
39. Bracamonte MP, Rud KS, Owen WG, Miller VM. Ovariectomy increases mitogens and platelet-induced proliferation of arterial smooth muscle. Am. J. Physiol. Heart Circ. Physiol. 2002 283 : H853 H60.
40. Fox SW, Chambers TJ. The effect of oestrogen on megakaryocyte differentiation and platelet counts in vivo. Int. J. Cardiol. 2005 109 : 359 66.
41. Khetawat G, Faraday N, Nealen ML et al. Human megakaryocytes and platelets contain the estrogen receptor β and androgen receptor (AR): Testosterone regulates AR expression. Blood 2000 95 : 2289 96.
42. Jayachandran M, Miller VM. Human platelets contain estrogen receptor α, caveolin-1 and estrogen receptor associated proteins. Platelets 2003 14 : 75 81.
43. Jayachandran M, Karnicki K, Miller RS, Owen WG, Korach KS, Miller VM. Platelet characteristics change with aging: Role of estrogen receptor β. J. Gerontol. Biol. Sci. 2005 60 : 815 19.
44. Jayachandran M, Okano H, Chatrath R, Owen WG, McConnell JP, Miller VM. Sex-specific changes in platelet aggregation and secretion with sexual maturity in pigs. J. Appl. Physiol. 2004 97 : 1445 52.
45. Jayachandran M, Mukherjee R, Steinkamp T et al. Differential effects of 17β-estradiol, conjugated equine estrogen and raloxifene on mRNA expression, aggregation and secretion in platelets. Am. J. Physiol. Heart Circ. Physiol. 2005 288 : H2355 62.
46. Jayachandran M, Owen WG, Miller VM. Effects of ovariectomy on aggregation, secretion, and metalloproteinases in porcine platelets. Am. J. Physiol. Heart Circ. Physiol. 2003 284 : H1679 85.
47. Jayachandran M, Sanzo A, Owen WG, Miller VM. Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets. Am. J. Physiol. Heart Circ. Physiol. 2005 289 : H1908 16.
48. Harman SM, Brinton EA, Cedars M et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005 8 : 3 12.
49. Torella D, Leosco D, Indolfi C et al. Aging exacerbates negative remodeling and impairs endothelial regeneration after balloon injury. Am. J. Physiol. Heart Circ. Physiol. 2004 287 : H2850 60.
50. Sumi D, Hayashi T, Jayachandran M, Iguchi A. Estrogen prevents destabilization of endothelial nitric oxide synthase mRNA induced by tumor necrosis factor α through estrogen receptor mediated system. Life Sci. 2001 69 : 1651 60.
51. Hisamoto K, Bender JR. Vascular cell signaling by membrane estrogen receptors. Steroids 2005 70 : 382 7.
52. Rosenfeld CR, White RE, Roy T, Cox BE. Calcium-activated potassium channels and nitric oxide coregulate estrogen-induced vasodilation. Am. J. Physiol. Heart Circ. Physiol. 2000 279 : H13 28.
53. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol. Endocrinol. 2005 19 : 1951 9.
54. Moro L, Reineri S, Piranda D et al. Non-genomic effects of 17β-estradiol in human platelets: Potentiation of thrombin-induced aggregation through estrogen receptor β and SRC kinase. Blood 2005 105 : 115 21.
55. Herrington DM, Fong J, Sempos CT et al. Comparison of the heart and estrogen/progestin replacement study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III). Am. Heart J. 1998 136 : 115 24.
56. Yang SH, Liu R, Perez EJ et al. Mitochondrial localization of estrogen receptor beta. Proc. Natl Acad. Sci. USA 2004 101 : 4130 5.
57. Chen J-Q, Yager JD, Russo J. Regulation of mitochondrial respiratory chain structure and function by estrogens/estrogen receptors and potential physiological/pathophysiological implications. Biochim. Biophys. Acta 2005 1746 : 1 17.
58. Chen JQ, Delannoy M, Cooke C, Yager JD. Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells. Am. J. Physiol. Endocrinol. Metab. 2004 286 : E1011 22.
59. Weinert BT, Timiras PS. Physiology of aging. Invited review: Theories of aging. J. Appl. Physiol. 2003 95 : 1706 16.
60. Hughes KA, Reynolds RM. Evolutionary and mechanistic theories of aging. Annu. Rev. Entomol. 2005 50 : 421 45.
61. Kanungo MS. A model for ageing. J. Theor. Biol. 1975 53 : 253 61.
62. Vina J, Borras C, Gambini J, Sastre J, Pallardo FV. Why females live longer than males? Importance of the upregulation of longevity-associated genes by oestrogenic compounds. FEBS Lett. 2005 579 : 2541 5.
63. Felty Q, Roy D. Mitochondrial signals to nucleus regulate estrogen-induced cell growth. Med. Hypotheses 2005 64 : 133 41.
64. Pich MM, Raule N, Catani L et al. Increased transcription of mitochondrial genes for complex I in human platelets during ageing. FEBS Lett. 2004 558 : 19 22.
65. Evinger III AJ, Levin ER. Requirements for estrogen receptor alpha membrane localization and function. Steroids 2005 70 : 361 3.
66. Cardona-Gomez GP, Mendez P, DonCarlos LL, Azcoitia I, Garcia-Segura LM. Interactions of estrogen and insulin-like growth factor-I in the brain: Molecular mechanisms and functional implications. J. Steroid Biochem. Mol. Biol. 2002 83 : 211 17.
67. Lenaz G, D'Aurelio M, Pich MM et al. Mitochondrial bioenergetics in aging. Biochim. Biophys. Acta 2000 1459 : 397 404.
68. Krotz F, Sohn H-Y, Pohl U. Reactive oxygen species. Players in the platelet game. Arterioscler. Thromb. Vasc. Biol. 2004 24 : 1988 96.
69. Biagini G, Pallotti F, Carraro S et al. Mitochondrial DNA in platelets from aged subjects. Mech. Ageing Dev. 1998 101 : 269 75.
70. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998 281 : 1309 12.
71. D'Aurelio M, Pich MM, Catani L et al. Decreased Pasteur effect in platelets of aged individuals. Mech. Ageing Dev. 2001 122 : 823 33.
72. Irani K, Pham Y, Coleman LD et al. Priming of platelet αIIbβ by oxidants is associated with tyrosine phosphorylation of β3. Arterioscler. Thromb. Vasc. Biol. 1998 18 : 1698 706.
73. Thattaliyath B, Cykowski M, Jagadeeswaran P. Young thrombocytes initiate the formation of arterial thrombus in zebrafish. Blood 2005 106 : 118 24.
74. Thijs A, van Baal WM, van der Mooren MJ et al. Effects of hormone replacement therapy on blood platelets. Eur. J. Clin. Invest. 2002 32 : 613 18.
75. Rand ML, Wang H, Bang KW, Poon KS, Packham MA, Freedman J. Procoagulant surface exposure and apoptosis in rabbit platelets. Association with shortened survival and steady-state senescence. J. Thromb. Haemost. 2004 2 : 651 9.
76. Miller ME, Dores GM, Thorpe SL, Akerley WL. Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thromb. Res. 1994 74 : 577 94.
77. Berger G, Hartwell DW, Wagner DD. P-Selectin and platelet clearance. Blood 1998 92 : 4446 52.
78. Herrington DM, Vittinghoff E, Howard TD et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler. Thromb. Vasc. Biol. 2002 22 : 1012 17.
79. Rosendaal FR, Vessey MP, Rumley A. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br. J. Haematol. 2002 116 : 851 4.
80. Braunstein JB, Warner Kershner D, Bray P et al. Interaction of hemostatic genetics with hormone therapy. New insights to explain arterial thrombosis in postmenopausal women. Chest 2002 121 : 906 20.
81. Zoller B, Berntsdotter A, Carcia de Frutos P, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995 85 : 3518 23.
82. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000 95 : 1517 32.
83. Herrington DM. Role of estrogen receptor-[alpha] in pharmacogenetics of estrogen action. Curr. Opin. Lipidol. 2003 14 : 145 50.
84. Shearman AM, Cupples LA, Demissie S et al. Association between estrogen receptor α gene variation and cardiovascular disease. JAMA 2003 290 : 2263 70.
85. Sudhir K, Chou TM, Messina LM et al. Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 1997 349 : 1146 7.
86. Kunnas TA, Laippala P, Penttila A, Lehtimaki T, Karhunen PJ. Association of polymorphism of human [alpha] oestrogen receptor gene with coronary artery disease in men: A necropsy study. BMJ 2000 321 : 273 4.
87. Post WA, Goldschmidt-Clermont PJ, Wilhide CC et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc. Res. 1999 43 : 985 91.
88. Tomasiak M, Stelmach H, Rusak T, Wysocka J. Nitric oxide and platelet energy metabolism. Acta Biochim. Pol. 2004 51 : 789 803.
89. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 2001 88 : 756 62.
90. Tanus-Santos JE, Desai M, Deak LR et al. Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics 2002 12 : 407 13.
91. Schreiber SN, Emter R, Hock MB et al. The estrogen-related receptor alpha (ERalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis. Proc. Natl Acad. Sci. USA 2004 101 : 6472 7.
92. Zhu Y, Bian Z, Lu P et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 2002 295 : 505 8.
93. Toorians AW, Thomassen MC, Zweegman S et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J. Clin. Endocrinol. Metab. 2003 88 : 5723 9.
94. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin. Endocrinol. 1997 47 : 337 42.